{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:37:09Z","timestamp":1794062229529,"version":"4.8.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2017HRTZYA"],"award-info":[{"award-number":["PRIN 2017HRTZYA"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2017N8CK4K"],"award-info":[{"award-number":["PRIN 2017N8CK4K"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Adrenal insufficiency (AI) is a severe endocrine disorder characterized by insufficient glucocorticoid (GC) and\/or mineralocorticoid (MC) secretion by the adrenal glands, due to impaired adrenal function (primary adrenal insufficiency, PAI) or to insufficient adrenal stimulation by pituitary ACTH (secondary adrenal insufficiency, SAI) or tertiary adrenal insufficiency due to hypothalamic dysfunction. In this review, we describe rare genetic causes of PAI with isolated GC or combined GC and MC deficiencies and we also describe rare syndromes of isolated MC deficiency. In children, the most frequent cause of PAI is congenital adrenal hyperplasia (CAH), a group of adrenal disorders related to steroidogenic enzyme deficiencies, which will not be included in this review. Less frequently, several rare diseases can cause PAI, either affecting exclusively the adrenal glands or with systemic involvement. The diagnosis of these diseases is often challenging, due to the heterogeneity of their clinical presentation and to their rarity. Therefore, the current review aims to provide an overview on these rare genetic forms of paediatric PAI, offering a review of genetic and clinical features and a summary of diagnostic and therapeutic approaches, promoting awareness among practitioners, and favoring early diagnosis and optimal clinical management in suspect cases.\n<\/jats:p>","DOI":"10.1007\/s11154-023-09784-7","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:21:18Z","timestamp":1676046078000},"page":"345-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rare forms of genetic paediatric adrenal insufficiency: Excluding congenital adrenal hyperplasia"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-6662","authenticated-orcid":false,"given":"Valeria","family":"Hasenmajer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-2405","authenticated-orcid":false,"given":"Rosario","family":"Ferrigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9091-2809","authenticated-orcid":false,"given":"Marianna","family":"Minnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0496-8997","authenticated-orcid":false,"given":"Bianca","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-5417","authenticated-orcid":false,"given":"Andrea M.","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7711-0465","authenticated-orcid":false,"given":"Andrea","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1310-3300","authenticated-orcid":false,"given":"Mariacarolina","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-7519","authenticated-orcid":false,"given":"Marco","family":"Cappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-8242","authenticated-orcid":false,"given":"Li","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3354-009X","authenticated-orcid":false,"given":"Maria Cristina","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7902-3376","authenticated-orcid":false,"given":"Martin O.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"10274","key":"9784_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","volume":"397","author":"ES Husebye","year":"2021","unstructured":"Husebye ES, Pearce SH, Krone NP, Kampe O. Adrenal insufficiency. Lancet. 2021;397(10274):613\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(21)00136-7.","journal-title":"Lancet"},{"issue":"1","key":"9784_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/endrev\/bnab016","volume":"43","author":"HL Claahsen-vanderGrinton","year":"2022","unstructured":"Claahsen-vanderGrinton HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022;43(1):91\u2013159. https:\/\/doi.org\/10.1210\/endrev\/bnab016.","journal-title":"Endocr Rev"},{"issue":"6","key":"9784_CR3","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1210\/edrv.19.6.0351","volume":"19","author":"AJ Clark","year":"1998","unstructured":"Clark AJ, Weber A. Adrenocorticotropin insensitivity syndromes. Endocr Rev. 1998;19(6):828\u201343. https:\/\/doi.org\/10.1210\/edrv.19.6.0351.","journal-title":"Endocr Rev"},{"issue":"1\u20132","key":"9784_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.mce.2012.12.010","volume":"371","author":"E Meimaridou","year":"2013","unstructured":"Meimaridou E, Hughes CR, Kowalczyk J, et al. Familial glucocorticoid deficiency: New genes and mechanisms. Mol Cell Endocrinol. 2013;371(1\u20132):195\u2013200. https:\/\/doi.org\/10.1016\/j.mce.2012.12.010.","journal-title":"Mol Cell Endocrinol"},{"key":"9784_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jsbmb.2019.02.012","volume":"189","author":"A Maharaj","year":"2019","unstructured":"Maharaj A, Maudhoo A, Chan LF, et al. Isolated glucocorticoid deficiency: Genetic causes and animal models. J Steroid Biochem Mol Biol. 2019;189:73\u201380. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.02.012.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"9784_CR6","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1210\/jc.2008-0034","volume":"93","author":"SM O'Riordan","year":"2008","unstructured":"O\u2019Riordan SM, Lynch SA, Hindmarsh PC, Chan LF, Clark AJ, Costigan C. A novel variant of familial glucocorticoid deficiency prevalent among the Irish Traveler population. J Clin Endocrinol Metab. 2008;93(7):2896\u20139. https:\/\/doi.org\/10.1210\/jc.2008-0034.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9784_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1172\/JCI60224","volume":"122","author":"CR Hughes","year":"2012","unstructured":"Hughes CR, Guasti L, Meimaridou E, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest. 2012;122(3):814\u201320. https:\/\/doi.org\/10.1172\/JCI60224.","journal-title":"J Clin Invest"},{"issue":"8843","key":"9784_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0140-6736(93)90208-x","volume":"341","author":"AJ Clark","year":"1993","unstructured":"Clark AJ, McLoughlin L, Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet. 1993;341(8843):461\u20132. https:\/\/doi.org\/10.1016\/0140-6736(93)90208-x.","journal-title":"Lancet"},{"key":"9784_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fendo.2015.00113","volume":"6","author":"LF Chan","year":"2015","unstructured":"Chan LF, Campbell DC, Novoselova TV, Clark AJ, Metherell LA. Whole-exome sequencing in the differential diagnosis of primary adrenal insufficiency in children. Front Endocrinol (Lausanne). 2015;6:113. https:\/\/doi.org\/10.3389\/fendo.2015.00113.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"9784_CR10","doi-asserted-by":"publisher","first-page":"bvab086","DOI":"10.1210\/jendso\/bvab086","volume":"5","author":"F Buonocore","year":"2021","unstructured":"Buonocore F, Maharaj A, Qamar Y, et al. Genetic analysis of pediatric primary adrenal insufficiency of unknown etiology: 25 years\u2019 experience in the UK. J Endocr Soc. 2021;5(8):bvab086. https:\/\/doi.org\/10.1210\/jendso\/bvab086.","journal-title":"J Endocr Soc"},{"issue":"15","key":"9784_CR11","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1073\/pnas.0809918106","volume":"106","author":"LF Chan","year":"2009","unstructured":"Chan LF, Webb TR, Chung TT, et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proc Natl Acad Sci U S A. 2009;106(15):6146\u201351. https:\/\/doi.org\/10.1073\/pnas.0809918106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6143","key":"9784_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1126\/science.1233000","volume":"341","author":"M Asai","year":"2013","unstructured":"Asai M, Ramachandrappa S, Joachim M, et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science. 2013;341(6143):275\u20138. https:\/\/doi.org\/10.1126\/science.1233000.","journal-title":"Science"},{"issue":"1","key":"9784_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/JOE-16-0057","volume":"230","author":"TV Novoselova","year":"2016","unstructured":"Novoselova TV, Larder R, Rimmington D, et al. Loss of Mrap2 is associated with Sim1 deficiency and increased circulating cholesterol. J Endocrinol. 2016;230(1):13\u201326. https:\/\/doi.org\/10.1530\/JOE-16-0057.","journal-title":"J Endocrinol"},{"issue":"2","key":"9784_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.beem.2018.02.002","volume":"32","author":"TV Novoselova","year":"2018","unstructured":"Novoselova TV, Chan LF, Clark AJL. Pathophysiology of melanocortin receptors and their accessory proteins. Best Pract Res Clin Endocrinol Metab. 2018;32(2):93\u2013106. https:\/\/doi.org\/10.1016\/j.beem.2018.02.002.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"9784_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/JOE-16-0638","volume":"236","author":"E Meimaridou","year":"2018","unstructured":"Meimaridou E, Goldsworthy M, Chortis V, et al. NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice. J Endocrinol. 2018;236(1):13\u201328. https:\/\/doi.org\/10.1530\/JOE-16-0638.","journal-title":"J Endocrinol"},{"issue":"10","key":"9784_CR16","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1210\/jc.2009-0467","volume":"94","author":"LA Metherell","year":"2009","unstructured":"Metherell LA, Naville D, Halaby G, et al. Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. J Clin Endocrinol Metab. 2009;94(10):3865\u201371. https:\/\/doi.org\/10.1210\/jc.2009-0467.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"9784_CR17","doi-asserted-by":"publisher","first-page":"E1556","DOI":"10.1210\/jc.2013-3844","volume":"99","author":"R Prasad","year":"2014","unstructured":"Prasad R, Chan LF, Hughes CR, et al. Thioredoxin Reductase 2 (TXNRD2) mutation associated with familial glucocorticoid deficiency (FGD). J Clin Endocrinol Metab. 2014;99(8):E1556-1563. https:\/\/doi.org\/10.1210\/jc.2013-3844.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9784_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2265.2009.03663.x","volume":"72","author":"TT Chung","year":"2010","unstructured":"Chung TT, Chan LF, Metherell LA, Clark AJ. Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2. Clin Endocrinol (Oxf). 2010;72(5):589\u201394. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03663.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"9784_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/cen.14131","volume":"92","author":"M Minnetti","year":"2020","unstructured":"Minnetti M, Caiulo S, Ferrigno R, et al. Abnormal linear growth in paediatric adrenal diseases: Pathogenesis, prevalence and management. Clin Endocrinol (Oxf). 2020;92(2):98\u2013108. https:\/\/doi.org\/10.1111\/cen.14131.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1\u20132","key":"9784_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/07435809509030439","volume":"21","author":"I Hanukoglu","year":"1995","unstructured":"Hanukoglu I, Rapoport R. Routes and regulation of NADPH production in steroidogenic mitochondria. Endocr Res. 1995;21(1\u20132):231\u201341. https:\/\/doi.org\/10.3109\/07435809509030439.","journal-title":"Endocr Res"},{"issue":"12","key":"9784_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ejmg.2015.11.001","volume":"58","author":"O Jazayeri","year":"2015","unstructured":"Jazayeri O, Liu X, van Diemen CC, et al. A novel homozygous insertion and review of published mutations in the NNT gene causing familial glucocorticoid deficiency (FGD). Eur J Med Genet. 2015;58(12):642\u20139. https:\/\/doi.org\/10.1016\/j.ejmg.2015.11.001.","journal-title":"Eur J Med Genet"},{"issue":"3","key":"9784_CR22","doi-asserted-by":"publisher","first-page":"H1227","DOI":"10.1152\/ajpheart.01162.2006","volume":"292","author":"C Berndt","year":"2007","unstructured":"Berndt C, Lillig CH, Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2007;292(3):H1227\u20131236. https:\/\/doi.org\/10.1152\/ajpheart.01162.2006.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"9784_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1530\/EJE-16-0056","volume":"175","author":"F Roucher-Boulez","year":"2016","unstructured":"Roucher-Boulez F, Mallet-Motak D, Samara-Boustani D, et al. NNT mutations: a cause of primary adrenal insufficiency, oxidative stress and extra-adrenal defects. Eur J Endocrinol. 2016;175(1):73\u201384. https:\/\/doi.org\/10.1530\/EJE-16-0056.","journal-title":"Eur J Endocrinol"},{"issue":"Pt A","key":"9784_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jsbmb.2016.03.009","volume":"165","author":"WL Miller","year":"2017","unstructured":"Miller WL. Disorders in the initial steps of steroid hormone synthesis. J Steroid Biochem Mol Biol. 2017;165(Pt A):18\u201337. https:\/\/doi.org\/10.1016\/j.jsbmb.2016.03.009.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"9784_CR25","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1210\/jc.2006-1565","volume":"91","author":"BY Baker","year":"2006","unstructured":"Baker BY, Lin L, Kim CJ, et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab. 2006;91(12):4781\u20135. https:\/\/doi.org\/10.1210\/jc.2006-1565.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9784_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2174\/1568009054629654","volume":"5","author":"M Lei","year":"2005","unstructured":"Lei M. The MCM complex: its role in DNA replication and implications for cancer therapy. Curr Cancer Drug Targets. 2005;5(5):365\u201380. https:\/\/doi.org\/10.2174\/1568009054629654.","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"9784_CR27","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1074\/jbc.274.8.4722","volume":"274","author":"SR Lee","year":"1999","unstructured":"Lee SR, Kim JR, Kwon KS, et al. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem. 1999;274(8):4722\u201334. https:\/\/doi.org\/10.1074\/jbc.274.8.4722.","journal-title":"J Biol Chem"},{"issue":"1","key":"9784_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.advenzreg.2009.10.024","volume":"50","author":"M Serra","year":"2010","unstructured":"Serra M, Saba JD. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul. 2010;50(1):349\u201362. https:\/\/doi.org\/10.1016\/j.advenzreg.2009.10.024.","journal-title":"Adv Enzyme Regul"},{"issue":"3","key":"9784_CR29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1172\/JCI90171","volume":"127","author":"R Prasad","year":"2017","unstructured":"Prasad R, Hadjidemetriou I, Maharaj A, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest. 2017;127(3):942\u201353. https:\/\/doi.org\/10.1172\/JCI90171.","journal-title":"J Clin Invest"},{"issue":"5","key":"9784_CR30","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1210\/jc.2018-02238","volume":"104","author":"N Settas","year":"2019","unstructured":"Settas N, Persky R, Faucz FR, et al. SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency. J Clin Endocrinol Metab. 2019;104(5):1484\u201390. https:\/\/doi.org\/10.1210\/jc.2018-02238.","journal-title":"J Clin Endocrinol Metab"},{"key":"9784_CR31","doi-asserted-by":"publisher","unstructured":"Zhu J, Eichler F, Biffi A, Duncan CN, Williams DA, Majzoub JA. The changing face of adrenoleukodystrophy. Endocr Rev. 2020;41(4). https:\/\/doi.org\/10.1210\/endrev\/bnaa013.","DOI":"10.1210\/endrev\/bnaa013"},{"key":"9784_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijdevneu.2019.11.002","author":"BR Turk","year":"2019","unstructured":"Turk BR, Theda C, Fatemi A, Moser AB. X-linked adrenoleukodystrophy: pathology, pathophysiology, diagnostic testing, newborn screening, and therapies. Int J Dev Neurosci. 2019. https:\/\/doi.org\/10.1016\/j.ijdevneu.2019.11.002.","journal-title":"Int J Dev Neurosci"},{"issue":"3","key":"9784_CR33","first-page":"481","volume":"76","author":"JM Powers","year":"1974","unstructured":"Powers JM, Schaumburg HH. Adreno-leukodystrophy (sex-linked Schilder\u2019s disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis. Am J Pathol. 1974;76(3):481\u201391.","journal-title":"Am J Pathol"},{"issue":"1","key":"9784_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1172\/JCI113292","volume":"81","author":"RW Whitcomb","year":"1988","unstructured":"Whitcomb RW, Linehan WM, Knazek RA. Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J Clin Invest. 1988;81(1):185\u20138. https:\/\/doi.org\/10.1172\/JCI113292.","journal-title":"J Clin Invest"},{"issue":"1","key":"9784_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MED.0000000000000515","volume":"27","author":"L Eng","year":"2020","unstructured":"Eng L, Regelmann MO. Adrenoleukodystrophy in the era of newborn screening. Curr Opin Endocrinol Diabetes Obes. 2020;27(1):47\u201355. https:\/\/doi.org\/10.1097\/MED.0000000000000515.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"7","key":"9784_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1590\/s0004-282x2012000700003","volume":"70","author":"CM Lourenco","year":"2012","unstructured":"Lourenco CM, Simao GN, Santos AC, Marques W Jr. X-linked adrenoleukodystrophy in heterozygous female patients: women are not just carriers. Arq Neuropsiquiatr. 2012;70(7):487\u201391. https:\/\/doi.org\/10.1590\/s0004-282x2012000700003.","journal-title":"Arq Neuropsiquiatr"},{"issue":"9","key":"9784_CR37","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","volume":"22","author":"AO Gupta","year":"2022","unstructured":"Gupta AO, Raymond G, Pierpont EI, et al. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy. Expert Opin Biol Ther. 2022;22(9):1151\u201362. https:\/\/doi.org\/10.1080\/14712598.2022.2124857.","journal-title":"Expert Opin Biol Ther"},{"issue":"1\u20132","key":"9784_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2010.07.006","volume":"297","author":"K Nakamura","year":"2010","unstructured":"Nakamura K, Yoshida K, Yoshinaga T, et al. Adult or late-onset triple A syndrome: case report and literature review. J Neurol Sci. 2010;297(1\u20132):85\u20138. https:\/\/doi.org\/10.1016\/j.jns.2010.07.006.","journal-title":"J Neurol Sci"},{"issue":"3","key":"9784_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/hmg\/10.3.283","volume":"10","author":"K Handschug","year":"2001","unstructured":"Handschug K, Sperling S, Yoon SJ, Hennig S, Clark AJ, Huebner A. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet. 2001;10(3):283\u201390. https:\/\/doi.org\/10.1093\/hmg\/10.3.283.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"9784_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3858\/emm.2009.41.6.043","volume":"41","author":"AR Cho","year":"2009","unstructured":"Cho AR, Yang KJ, Bae Y, et al. Tissue-specific expression and subcellular localization of ALADIN, the absence of which causes human triple A syndrome. Exp Mol Med. 2009;41(6):381\u20136. https:\/\/doi.org\/10.3858\/emm.2009.41.6.043.","journal-title":"Exp Mol Med"},{"issue":"12","key":"9784_CR41","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1210\/me.2009-0056","volume":"23","author":"HL Storr","year":"2009","unstructured":"Storr HL, Kind B, Parfitt DA, et al. Deficiency of ferritin heavy-chain nuclear import in triple a syndrome implies nuclear oxidative damage as the primary disease mechanism. Mol Endocrinol. 2009;23(12):2086\u201394. https:\/\/doi.org\/10.1210\/me.2009-0056.","journal-title":"Mol Endocrinol"},{"issue":"11","key":"9784_CR42","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1242\/bio.021162","volume":"5","author":"R Juhlen","year":"2016","unstructured":"Juhlen R, Landgraf D, Huebner A, Koehler K. Identification of a novel putative interaction partner of the nucleoporin ALADIN. Biol Open. 2016;5(11):1697\u2013705. https:\/\/doi.org\/10.1242\/bio.021162.","journal-title":"Biol Open"},{"issue":"12","key":"9784_CR43","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/0929866527666200613215449","volume":"27","author":"G Pogliaghi","year":"2020","unstructured":"Pogliaghi G, Cangiano B, Duminuco P, Vezzoli V, Bonomi M. Triple-A Syndrome (TAS): An in-depth overview on genetic and phenotype heterogeneity. Protein Pept Lett. 2020;27(12):1192\u2013203. https:\/\/doi.org\/10.2174\/0929866527666200613215449.","journal-title":"Protein Pept Lett"},{"issue":"8077","key":"9784_CR44","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/s0140-6736(78)91268-0","volume":"1","author":"J Allgrove","year":"1978","unstructured":"Allgrove J, Clayden GS, Grant DB, Macaulay JC. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet. 1978;1(8077):1284\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(78)91268-0.","journal-title":"Lancet"},{"issue":"8","key":"9784_CR45","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/1744666X.2021.1925543","volume":"17","author":"N Sharifinejad","year":"2021","unstructured":"Sharifinejad N, Zaki-Dizaji M, Tebyanian S, et al. Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review. Expert Rev Clin Immunol. 2021;17(8):807\u201317. https:\/\/doi.org\/10.1080\/1744666X.2021.1925543.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"9784_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00005792-198109000-00003","volume":"60","author":"M Neufeld","year":"1981","unstructured":"Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison\u2019s disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore). 1981;60(5):355\u201362. https:\/\/doi.org\/10.1097\/00005792-198109000-00003.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"9784_CR47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ng1297-399","volume":"17","author":"AC Finnish-German","year":"1997","unstructured":"Finnish-German AC. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997;17(4):399\u2013403. https:\/\/doi.org\/10.1038\/ng1297-399.","journal-title":"Nat Genet"},{"key":"9784_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coi.2016.07.003","volume":"43","author":"O Bruserud","year":"2016","unstructured":"Bruserud O, Oftedal BE, Wolff AB, Husebye ES. AIRE-mutations and autoimmune disease. Curr Opin Immunol. 2016;43:8\u201315. https:\/\/doi.org\/10.1016\/j.coi.2016.07.003.","journal-title":"Curr Opin Immunol"},{"issue":"26","key":"9784_CR49","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1056\/NEJM199006283222601","volume":"322","author":"P Ahonen","year":"1990","unstructured":"Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322(26):1829\u201336. https:\/\/doi.org\/10.1056\/NEJM199006283222601.","journal-title":"N Engl J Med"},{"issue":"9","key":"9784_CR50","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1210\/jc.2017-00139","volume":"102","author":"EM Orlova","year":"2017","unstructured":"Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. J Clin Endocrinol Metab. 2017;102(9):3546\u201356. https:\/\/doi.org\/10.1210\/jc.2017-00139.","journal-title":"J Clin Endocrinol Metab"},{"key":"9784_CR51","doi-asserted-by":"publisher","first-page":"619041","DOI":"10.3389\/fped.2020.619041","volume":"8","author":"F Buonocore","year":"2020","unstructured":"Buonocore F, McGlacken-Byrne SM, Del Valle I, Achermann JC. Current insights into adrenal insufficiency in the newborn and young infant. Front Pediatr. 2020;8:619041. https:\/\/doi.org\/10.3389\/fped.2020.619041.","journal-title":"Front Pediatr"},{"issue":"6","key":"9784_CR52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.immuni.2015.04.021","volume":"42","author":"BE Oftedal","year":"2015","unstructured":"Oftedal BE, Hellesen A, Erichsen MM, et al. Dominant mutations in the autoimmune regulator AIRE Are associated with common organ-specific autoimmune diseases. Immunity. 2015;42(6):1185\u201396. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.021.","journal-title":"Immunity"},{"issue":"1","key":"9784_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.autrev.2017.11.012","volume":"17","author":"CJ Guo","year":"2018","unstructured":"Guo CJ, Leung PSC, Zhang W, Ma X, Gershwin ME. The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). Autoimmun Rev. 2018;17(1):78\u201385. https:\/\/doi.org\/10.1016\/j.autrev.2017.11.012.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"9784_CR54","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/jmg.29.11.824","volume":"29","author":"J Zlotogora","year":"1992","unstructured":"Zlotogora J, Shapiro MS. Polyglandular autoimmune syndrome type I among Iranian Jews. J Med Genet. 1992;29(11):824\u20136. https:\/\/doi.org\/10.1136\/jmg.29.11.824.","journal-title":"J Med Genet"},{"issue":"6","key":"9784_CR55","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1210\/jcem.87.6.8564","volume":"87","author":"M Halonen","year":"2002","unstructured":"Halonen M, Eskelin P, Myhre AG, et al. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab. 2002;87(6):2568\u201374. https:\/\/doi.org\/10.1210\/jcem.87.6.8564.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9784_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13052-016-0282-3","volume":"42","author":"C Bizzarri","year":"2016","unstructured":"Bizzarri C, Olivini N, Pedicelli S, et al. Congenital primary adrenal insufficiency and selective aldosterone defects presenting as salt-wasting in infancy: a single center 10-year experience. Ital J Pediatr. 2016;42(1):73. https:\/\/doi.org\/10.1186\/s13052-016-0282-3.","journal-title":"Ital J Pediatr"},{"issue":"4","key":"9784_CR57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.beem.2015.07.004","volume":"29","author":"JP Suntharalingham","year":"2015","unstructured":"Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC. DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. Best Pract Res Clin Endocrinol Metab. 2015;29(4):607\u201319. https:\/\/doi.org\/10.1016\/j.beem.2015.07.004.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"9784_CR58","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1210\/jc.2006-0603","volume":"91","author":"L Lin","year":"2006","unstructured":"Lin L, Gu WX, Ozisik G, et al. Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years\u2019 experience. J Clin Endocrinol Metab. 2006;91(8):3048\u201354. https:\/\/doi.org\/10.1210\/jc.2006-0603.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"9784_CR59","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1210\/jcem.83.8.5027","volume":"83","author":"M Peter","year":"1998","unstructured":"Peter M, Viemann M, Partsch CJ, Sippell WG. Congenital adrenal hypoplasia: clinical spectrum, experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene. J Clin Endocrinol Metab. 1998;83(8):2666\u201374. https:\/\/doi.org\/10.1210\/jcem.83.8.5027.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9784_CR60","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1210\/jcem.84.2.5468","volume":"84","author":"AT Reutens","year":"1999","unstructured":"Reutens AT, Achermann JC, Ito M, et al. Clinical and functional effects of mutations in the DAX-1 gene in patients with adrenal hypoplasia congenita. J Clin Endocrinol Metab. 1999;84(2):504\u201311. https:\/\/doi.org\/10.1210\/jcem.84.2.5468.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9784_CR61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2265.2009.03652.x","volume":"72","author":"Z Landau","year":"2010","unstructured":"Landau Z, Hanukoglu A, Sack J, et al. Clinical and genetic heterogeneity of congenital adrenal hypoplasia due to NR0B1 gene mutations. Clin Endocrinol (Oxf). 2010;72(4):448\u201354. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03652.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"9784_CR62","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1515\/jpem-2018-0445","volume":"32","author":"M Wijaya","year":"2019","unstructured":"Wijaya M, Huamei M, Jun Z, et al. Etiology of primary adrenal insufficiency in children: a 29-year single-center experience. J Pediatr Endocrinol Metab. 2019;32(6):615\u201322. https:\/\/doi.org\/10.1515\/jpem-2018-0445.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"9784_CR63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/js.2018-00270","volume":"3","author":"C Suthiworachai","year":"2019","unstructured":"Suthiworachai C, Tammachote R, Srichomthong C, et al. Identification and functional analysis of Six DAX1 mutations in patients with X-Linked adrenal hypoplasia congenita. J Endocr Soc. 2019;3(1):171\u201380. https:\/\/doi.org\/10.1210\/js.2018-00270.","journal-title":"J Endocr Soc"},{"issue":"3","key":"9784_CR64","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1210\/clinem\/dgaa881","volume":"106","author":"D Capalbo","year":"2021","unstructured":"Capalbo D, Moracas C, Cappa M, et al. Primary adrenal insufficiency in childhood: data from a large nationwide cohort. J Clin Endocrinol Metab. 2021;106(3):762\u201373. https:\/\/doi.org\/10.1210\/clinem\/dgaa881.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"9784_CR65","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/ng.2275","volume":"44","author":"VA Arboleda","year":"2012","unstructured":"Arboleda VA, Lee H, Parnaik R, et al. Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat Genet. 2012;44(7):788\u201392. https:\/\/doi.org\/10.1038\/ng.2275.","journal-title":"Nat Genet"},{"issue":"6","key":"9784_CR66","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.ajhg.2018.10.024","volume":"103","author":"CV Logan","year":"2018","unstructured":"Logan CV, Murray JE, Parry DA, et al. DNA polymerase epsilon deficiency causes IMAGe syndrome with variable immunodeficiency. Am J Hum Genet. 2018;103(6):1038\u201344. https:\/\/doi.org\/10.1016\/j.ajhg.2018.10.024.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"9784_CR67","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6065\/apem.2142150.075","volume":"26","author":"HW Yoo","year":"2021","unstructured":"Yoo HW. Diverse etiologies, diagnostic approach, and management of primary adrenal insufficiency in pediatric age. Ann Pediatr Endocrinol Metab. 2021;26(3):149\u201357. https:\/\/doi.org\/10.6065\/apem.2142150.075.","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"7\u20138","key":"9784_CR68","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1515\/jpem.2011.230","volume":"24","author":"SM O'Connell","year":"2011","unstructured":"O\u2019Connell SM, Johnson SR, Lewis BD, et al. Structural chromosome disruption of the NR3C2 gene causing pseudohypoaldosteronism type 1 presenting in infancy. J Pediatr Endocrinol Metab. 2011;24(7\u20138):555\u20139. https:\/\/doi.org\/10.1515\/jpem.2011.230.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9","key":"9784_CR69","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1210\/jc.2006-0605","volume":"91","author":"FL Fernandes-Rosa","year":"2006","unstructured":"Fernandes-Rosa FL, de Castro M, Latronico AC, Sippell WG, Riepe FG, Antonini SR. Recurrence of the R947X mutation in unrelated families with autosomal dominant pseudohypoaldosteronism type 1: evidence for a mutational hot spot in the mineralocorticoid receptor gene. J Clin Endocrinol Metab. 2006;91(9):3671\u20135. https:\/\/doi.org\/10.1210\/jc.2006-0605.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9784_CR70","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1515\/jpem-2018-0538","volume":"32","author":"JS Gopal-Kothandapani","year":"2019","unstructured":"Gopal-Kothandapani JS, Doshi AB, Smith K, et al. Phenotypic diversity and correlation with the genotypes of pseudohypoaldosteronism type 1. J Pediatr Endocrinol Metab. 2019;32(9):959\u201367. https:\/\/doi.org\/10.1515\/jpem-2018-0538.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"9784_CR71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1297\/cpe.26.109","volume":"26","author":"T Tajima","year":"2017","unstructured":"Tajima T, Morikawa S, Nakamura A. Clinical features and molecular basis of pseudohypoaldosteronism type 1. Clin Pediatr Endocrinol. 2017;26(3):109\u201317. https:\/\/doi.org\/10.1297\/cpe.26.109.","journal-title":"Clin Pediatr Endocrinol"},{"issue":"4","key":"9784_CR72","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/nep.13391","volume":"24","author":"T Tanaka","year":"2019","unstructured":"Tanaka T, Oki E, Mori T, et al. Complete clinical resolution of a Japanese family with renal pseudohypoaldosteronism type 1 due to a novel NR3C2 mutation. Nephrology (Carlton). 2019;24(4):489\u201390. https:\/\/doi.org\/10.1111\/nep.13391.","journal-title":"Nephrology (Carlton)"},{"key":"9784_CR73","doi-asserted-by":"publisher","first-page":"130010","DOI":"10.1530\/EDM-13-0010","volume":"2013","author":"N Amin","year":"2013","unstructured":"Amin N, Alvi NS, Barth JH, et al. Pseudohypoaldosteronism type 1: clinical features and management in infancy. Endocrinol Diabetes Metab Case Rep. 2013;2013:130010. https:\/\/doi.org\/10.1530\/EDM-13-0010.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"9784_CR74","doi-asserted-by":"publisher","first-page":"524647","DOI":"10.1155\/2013\/524647","volume":"2013","author":"SA Bowden","year":"2013","unstructured":"Bowden SA, Cozzi C, Hickey SE, Thrush DL, Astbury C, Nuthakki S. Autosomal dominant pseudohypoaldosteronism type 1 in an infant with salt wasting crisis associated with urinary tract infection and obstructive uropathy. Case Rep Endocrinol. 2013;2013:524647. https:\/\/doi.org\/10.1155\/2013\/524647.","journal-title":"Case Rep Endocrinol"},{"issue":"2","key":"9784_CR75","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2019.07.026","volume":"519","author":"LP Yin","year":"2019","unstructured":"Yin LP, Zhu H, Zhu RY, Huang L. A novel SCNN1G mutation in a PHA I infant patient correlates with nephropathy. Biochem Biophys Res Commun. 2019;519(2):415\u201321. https:\/\/doi.org\/10.1016\/j.bbrc.2019.07.026.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"9784_CR76","doi-asserted-by":"publisher","first-page":"bvab095","DOI":"10.1210\/jendso\/bvab095","volume":"5","author":"AS Alzahrani","year":"2021","unstructured":"Alzahrani AS, Alswailem M, Abbas BB, et al. A Unique genotype of pseudohypoaldosteronism Type 1b in a highly consanguineous population. J Endocr Soc. 2021;5(8):bvab095. https:\/\/doi.org\/10.1210\/jendso\/bvab095.","journal-title":"J Endocr Soc"},{"issue":"2","key":"9784_CR77","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4274\/jcrpe.v3i2.20","volume":"3","author":"T Guran","year":"2011","unstructured":"Guran T, Degirmenci S, Bulut IK, Say A, Riepe FG, Guran O. Critical points in the management of pseudohypoaldosteronism type 1. J Clin Res Pediatr Endocrinol. 2011;3(2):98\u2013100. https:\/\/doi.org\/10.4274\/jcrpe.v3i2.20.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"6","key":"9784_CR78","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ccr3.129","volume":"2","author":"G Kala Ahluwalia","year":"2014","unstructured":"Kala Ahluwalia G, Dasouki M, Lennon A. Phenotypic variation of autosomal recessive pseudohypoaldosteronism type I: a case in point. Clin Case Rep. 2014;2(6):326\u201330. https:\/\/doi.org\/10.1002\/ccr3.129.","journal-title":"Clin Case Rep"},{"issue":"2","key":"9784_CR79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4274\/jcrpe.galenos.2020.2019.0216","volume":"13","author":"H Turan","year":"2021","unstructured":"Turan H, Dagdeviren Cakir A, Ozer Y, et al. Clinical and genetic characteristics of patients with corticosterone methyloxidase deficiency Type 2: novel mutations in CYP11B2. J Clin Res Pediatr Endocrinol. 2021;13(2):232\u20138. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2020.2019.0216.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"9784_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2003.10.013","author":"PC White","year":"2004","unstructured":"White PC. Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol. 2004. https:\/\/doi.org\/10.1016\/j.mce.2003.10.013.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"9784_CR81","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1210\/clinem\/dgaa765","volume":"106","author":"C Merakou","year":"2021","unstructured":"Merakou C, Fylaktou I, Sertedaki A, et al. Molecular analysis of the CYP11B2 gene in 62 patients with hypoaldosteronism due to aldosterone synthase deficiency. J Clin Endocrinol Metab. 2021;106(1):e182\u201391. https:\/\/doi.org\/10.1210\/clinem\/dgaa765.","journal-title":"J Clin Endocrinol Metab"},{"key":"9784_CR82","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab619","author":"BKDY Gurpinar Tosun","year":"2021","unstructured":"Gurpinar Tosun BKDY, Seven Menevse T, Kaygusuz SB, Ozbek MN, Altincik SA, Mammadova J, Cayir A, Doger E, Bayramoglu E, Nalbantoglu O, Yesiltepe Mutlu G, Aghayev A, Turan S, Bereket A, Guran T. Catch-up growth and discontinuation of fludrocortisone treatment in aldosterone synthase deficiency. J Clin Endocrinol Metab. 2021. https:\/\/doi.org\/10.1210\/clinem\/dgab619.","journal-title":"J Clin Endocrinol Metab"},{"key":"9784_CR83","unstructured":"Arai KP-MN, Chrousos GP. Aldosterone Deficiency and Resistance. 2020 Nov 24. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, et al, editors. Aldosterone Deficiency and Resistance. Endotext [Internet]. South Dartmouth: MDText.com, Inc.; 2000."},{"issue":"1","key":"9784_CR84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.anpedi.2010.04.008","volume":"73","author":"O Rubio-Cabezas","year":"2010","unstructured":"Rubio-Cabezas O, Regueras L, Munoz-Calvo MT, Bartolome M, Pozo J, Argente J. Primary hypoaldosteronism and moderate bilateral deafness in a child with a homozygous missense mutation (Thr318Met) in the CYP11B2 gene. An Pediatr (Barc). 2010;73(1):31\u20134. https:\/\/doi.org\/10.1016\/j.anpedi.2010.04.008.","journal-title":"An Pediatr (Barc)"},{"issue":"2","key":"9784_CR85","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364\u201389. https:\/\/doi.org\/10.1210\/jc.2015-1710.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9784_CR86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/cen.13232","volume":"86","author":"E Sbardella","year":"2017","unstructured":"Sbardella E, Isidori AM, Woods CP, et al. Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays. Clin Endocrinol (Oxf). 2017;86(2):177\u201384. https:\/\/doi.org\/10.1111\/cen.13232.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"9784_CR87","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40618-019-01146-y","volume":"43","author":"AM Isidori","year":"2020","unstructured":"Isidori AM, Arnaldi G, Boscaro M, et al. Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. J Endocrinol Invest. 2020;43(5):683\u201396. https:\/\/doi.org\/10.1007\/s40618-019-01146-y.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"9784_CR88","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jc.2011-1926","volume":"97","author":"G Johannsson","year":"2012","unstructured":"Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012;97(2):473\u201381. https:\/\/doi.org\/10.1210\/jc.2011-1926.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9784_CR89","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"AM Isidori","year":"2018","unstructured":"Isidori AM, Venneri MA, Graziadio C, et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):173\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(17)30398-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"9784_CR90","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/17446651.2018.1455496","volume":"13","author":"J Porter","year":"2018","unstructured":"Porter J, Withe M, Ross RJ. Immediate-release granule formulation of hydrocortisone, Alkindi(R), for treatment of paediatric adrenal insufficiency (Infacort development programme). Expert Rev Endocrinol Metab. 2018;13(3):119\u201324. https:\/\/doi.org\/10.1080\/17446651.2018.1455496.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"9784_CR91","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40272-018-0306-0","volume":"20","author":"J Park","year":"2018","unstructured":"Park J, Das U, Didi M, et al. The challenges of cortisol replacement therapy in childhood: Observations from a case series of children treated with modified-release hydrocortisone. Paediatr Drugs. 2018;20(6):567\u201373. https:\/\/doi.org\/10.1007\/s40272-018-0306-0.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"9784_CR92","doi-asserted-by":"publisher","first-page":"e1433","DOI":"10.1210\/clinem\/dgaa626","volume":"106","author":"U Neumann","year":"2021","unstructured":"Neumann U, Braune K, Whitaker MJ, et al. A prospective study of children aged 0\u20138 years with CAH and adrenal insufficiency treated with hydrocortisone granules. J Clin Endocrinol Metab. 2021;106(3):e1433\u201340. https:\/\/doi.org\/10.1210\/clinem\/dgaa626.","journal-title":"J Clin Endocrinol Metab"},{"key":"9784_CR93","doi-asserted-by":"publisher","unstructured":"Saito J, Yoshikawa N, Hanawa T, et al. Stability of hydrocortisone in oral powder form compounded for pediatric patients in Japan. Pharmaceutics. 2021;13(8). https:\/\/doi.org\/10.3390\/pharmaceutics13081267.","DOI":"10.3390\/pharmaceutics13081267"},{"key":"9784_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2020-319865","author":"M Shaunak","year":"2020","unstructured":"Shaunak M, Banerjee I, Davies JH. Hydrocortisone muco-adhesive buccal tablets continue to be used for the treatment of adrenal insufficiency in children in the UK. Arch Dis Child. 2020. https:\/\/doi.org\/10.1136\/archdischild-2020-319865.","journal-title":"Arch Dis Child"},{"issue":"3","key":"9784_CR95","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.beem.2015.04.002","volume":"29","author":"EA Webb","year":"2015","unstructured":"Webb EA, Krone N. Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2015;29(3):449\u201368. https:\/\/doi.org\/10.1016\/j.beem.2015.04.002.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"9784_CR96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/jim-2019-000999","volume":"68","author":"BS Miller","year":"2020","unstructured":"Miller BS, Spencer SP, Mitchell E, et al. Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings. J Investig Med. 2020;68(1):16\u201325. https:\/\/doi.org\/10.1136\/jim-2019-000999.","journal-title":"J Investig Med"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-023-09784-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-023-09784-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-023-09784-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T02:19:57Z","timestamp":1679105997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-023-09784-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["9784"],"URL":"https:\/\/doi.org\/10.1007\/s11154-023-09784-7","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"3 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VH, RF, MM, BP, AL, MCS, MC, MCDM, MOS have nothing to disclose. A.M.I. does consultancy for Novartis, Takeda, Recordati, and Sandoz companies and has received research grants and honoraria from Shire, IPSEN, and Pfizer company. LC does consultancy for OMass therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial or non-financial interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no conflicts of interest to report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}